Russell 3000 Adds Ocugen, Nektar; Nano-X Drops in Healthcare Reshuffle
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
russell-3000index-reshuffle
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
FTSE Russell announced its preliminary list of additions and deletions for the Russell 3000 index on May 26, 2026. The annual reconstitution will see biopharmaceutical firms Ocugen, Inc. and Nektar Therapeutics join the broad market index. Nano-X Imaging Ltd. is slated for removal. The changes, based on market capitalization rankings as of April 30, become effective at the market open on June 27, 2026. This event directly influences the allocation of an estimated $12 trillion in institutional assets that benchmark or replicate the index.
The Russell US indexes undergo a comprehensive reconstitution each May, finalizing membership based on market cap and public float. This process ensures the indexes remain accurate representations of the US equity market. The last major healthcare reshuffle occurred in 2023, when more than a dozen biotech firms entered during a sector rally. The current macro backdrop features the 10-year Treasury yield at 4.31% and the S&P 500 healthcare sector posting a modest year-to-date gain of 3.7%. The trigger for this year's changes is the recalculation of market capitalizations following a period of significant volatility for small and mid-cap healthcare stocks. Companies that have sustained or achieved a market cap above the qualifying threshold secure their inclusion.
The Russell 3000 index represents approximately 98% of the investable US equity market. Ocugen entered the inclusion list with a market capitalization of approximately $950 million. Nektar Therapeutics qualified with a market cap of $1.2 billion. Nano-X Imaging fell below the threshold for inclusion with a market cap of roughly $580 million. For comparison, the median market cap of a Russell 3000 component is $3.1 billion. The index's total market cap is approximately $48 trillion. The iShares Russell 3000 ETF (IWV) holds over $13 billion in assets under management. The annual turnover for the index typically affects 3-5% of its constituents.
| Ticker | Action | Market Cap (Billion USD) | YTD Price Change (%) |
|---|---|---|---|
| OCGN | Add | ~$0.95 | +42.1 |
| NKTR | Add | ~$1.20 | +18.5 |
| NNOX | Delete | ~$0.58 | -22.3 |
Index inclusion typically generates immediate buying pressure from passive funds that track the Russell 3000. Ocugen and Nektar could see a collective inflow of $150-$250 million from index funds and ETFs over the five days surrounding the effective date. Conversely, Nano-X Imaging faces selling pressure from these same funds as it is deleted. The broader healthcare sector may see increased attention from active managers scanning for the next potential index addition. A key limitation is that index inclusion is a technical, not fundamental, driver; it does not guarantee long-term outperformance. Historical data shows that the price impact from reconstitution-related trading often peaks within a week of the effective date. Flow data indicates hedge funds often position ahead of the official announcement, attempting to front-run passive fund buying.
The final confirmed list of additions and deletions will be published on June 5, 2026, after the market close. Trading volume for the affected securities will intensify significantly in the week leading up to the June 27 effective date. Key levels to watch are the $1 billion market cap level, a critical threshold for many small-cap indices. The next major catalyst for small-cap performance is the Q2 2026 earnings season, commencing in mid-July. The performance of the Russell 2000 index relative to the Russell 1000 will indicate risk appetite for smaller companies. If Treasury yields remain stable, the environment could be favorable for new index constituents to retain their gains.
Retail investors holding shares of a company added to the Russell 3000 often benefit from increased liquidity and a short-term price bump due to forced buying by index funds. However, this is a technical effect. Long-term performance remains tied to the company's fundamentals, not its index membership. Retail traders should be aware of potential volatility around the effective date as large institutional orders are executed.
The Russell 3000 reconstitution is an annual, rules-based process driven solely by market capitalization rankings. The S&P 500 committee makes quarterly adjustments based on market cap, liquidity, and sector representation, among other factors. The Russell process is entirely quantitative and predictable, while the S&P process includes a qualitative, discretionary element.
Academic studies show a consistent pattern: stocks experience abnormal positive returns in the days immediately preceding and following their addition. A 2022 study found an average excess return of 3.2% in the five-day window around effective dates. However, these gains often partially reverse over the subsequent six months as the technical buying pressure subsides and fundamentals reassert themselves.
The annual index reshuffle forces billions in institutional capital to flow into new additions and out of deletions.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.